The landscape of patients with metastatic breast cancer enrolled in phase I trials

被引：0
|
作者：
Marra [1 ]
Criscitiello, C. [2 ]
Morganti, S. [1 ]
Zagami, P. [1 ]
Viale, G. [1 ]
Tarantino, P. [1 ]
Trapani, D. [1 ]
Nicolo, E. [1 ]
Repetto, M. [1 ]
Ferraro, E. [1 ]
D'Amico, P. [1 ]
Locatelli, M. [2 ]
Esposito, A. [2 ]
Curigliano, G. [1 ]
机构：
[1] Univ Milan, European Inst Oncol IRCCS, Dept Oncol & Haematooncol, Div Early Drug Dev Innovat Therapies,IEO, Milan, Italy
[2] European Inst Oncol IRCCS, IEO, Div Early Drug Dev Innovat Therapies, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S70 / S71
页数：2
相关论文
共 50 条
  • [31] Global trends in phase I trials: Changes in cancer types of enrolled patients in 1991-2015.
    Itahashi, Kota
    Shimizu, Toshio
    Koyama, Takafumi
    Kondo, Shunsuke
    Fujiwara, Yutaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials
    Levy, Antonin
    Gomez-Roca, Carlos
    Massard, Christophe
    Planchard, David
    Albiges, Laurence
    Bahleda, Ratislav
    Bourgier, Celine
    Deutsch, Eric
    Soria, Jean Charles
    Besse, Benjamin
    ONKOLOGIE, 2013, 36 (06): : 357 - 362
  • [33] Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center
    Ouali, K.
    Mateus, C.
    Laparra, A.
    Pavliuc, E.
    Romano, P. Martin
    Sampetrean, A.
    Varga, A.
    Champiat, S.
    Verlingue, L.
    Geraud, A.
    Marabelle, A.
    Hollebecque, A.
    Gazzah, A.
    Bahleda, R.
    Postel-Vinay, S.
    Ribrag, V.
    Soria, J-C.
    Scotte, F.
    Massard, C.
    Baldini, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1079 - S1079
  • [34] Phase I Study of Oral Vinorelbine and Capecitabine in Patients with Metastatic Breast Cancer
    Anton, Antonio
    Lluch, Ana
    Casado, Antonio
    Provencio, Mariano
    Munoz, Montserrat
    Lao, Juan
    Bermejo, Begona
    Paules, Ana B.
    Gayo, Javier
    Martin, Miguel
    ANTICANCER RESEARCH, 2010, 30 (06) : 2255 - 2261
  • [35] A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer
    Roche, Henri
    De Benedictis, Elena
    Cottura, Ewa
    Govi, Silvia
    Dalenc, Florence
    Locatelli, Alberta
    Deslandres, Marion
    Zambetti, Milvia
    Gladieff, Laurence
    Messina, Marianne
    Gianni, Luca
    CLINICAL BREAST CANCER, 2012, 12 (03) : 167 - 174
  • [36] Gemcitabine and epirubicin in patients with metastatic breast cancer:: A phase I/II study
    Campone, Mario
    Fumoleau, Pierre
    Viens, Patrice
    Dieras, Wronique
    Pujade-Lauraine, Eric
    Serin, Daniel
    Petit, Thierry
    Espie, Marc
    Kayitalire, Louis
    Bozec, Laurence
    Pouillart, Pierre
    BREAST, 2006, 15 (05): : 601 - 609
  • [37] PHASE-I TRIAL OF DROLOXIFENE IN PATIENTS WITH METASTATIC BREAST-CANCER
    BUZDAR, AU
    KAU, S
    HORTOBAGYI, GN
    THERIAULT, RL
    BOOSER, D
    HOLMES, FA
    WALTERS, R
    KRAKOFF, IH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 (04) : 313 - 316
  • [38] Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
    Hyman, David M.
    Eaton, Anne A.
    Gounder, Mrinal M.
    Pamer, Erika G.
    Pettiford, Jasmine
    Carvajal, Richard D.
    Ivy, S. Percy
    Iasonos, Alexia
    Spriggs, David R.
    ONCOTARGET, 2015, 6 (22) : 19316 - 19327
  • [39] Outcome and characteristics of patients with advanced gynaecological malignancies enrolled in phase I trials
    Rouge, T. de La Motte
    Roca, C. Gomez
    Bahleda, R.
    Gombos, A.
    Pautier, P.
    Soria, J. C.
    Lhomme, C.
    Massard, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 136 - 136
  • [40] MOSCATO: a Molecular Screening Triage Trial for Patients Enrolled in Phase I Trials
    Massard, C.
    Auger, N.
    Vielh, P.
    Lacroix, L.
    Lazar, V.
    Ngocamus, M.
    Le Deley, M. C.
    Andre, F.
    DeBaere, T.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 188 - 189
12345